46 results
Page 2 of 3
6-K
EX-99.1
2t9hgy9bbx
5 Jan 22
Current report (foreign)
7:30am
6-K
EX-99.2
lct6zgqaoi3d xd2n
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.3
nlkmzogj hgk4153
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.3
1ki54fdtl 2zhzsod5
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.3
1u2mr209sgc b6ev6
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
snqtq
25 Mar 21
InflaRx Reports Full Year 2020 Financial & Operating Results
7:28am
6-K
EX-99.2
08ayyw6kajlmjzo u2s
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.3
x7duwkuodx vw
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.1
d1i1ir0l59f64sav
14 Sep 20
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia
7:36am
6-K
EX-99.3
88ndbky
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
0toql5caew 9jkwlwvea
21 Jul 20
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
7:35am
6-K
EX-99.1
jnht7tkztob
17 Jun 20
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
7:30am
6-K
EX-99.3
rujq9y iwh
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.1
oozoun1npsb83hr yc12
29 Apr 20
InflaRx Reports Full Year 2019 Financial & Operating Results
8:00am
6-K
EX-99.1
ik323lni0fg9k
9 Apr 20
Controlling inflammation LIFESCI CAPITAL ALPHA SERIES CONFERENCE 2020
7:26am
6-K
EX-99.3
rhe69m
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.1
egcjq ysi
16 Jan 20
CONTROLLING INFLAMMATION JP Morgan Corporate Presentation January 2020
4:11pm
6-K
EX-99.3
q4ubieq5ci9ppsy01
7 Nov 19
Current report (foreign)
7:00am